JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $57
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Apellis Pharmaceuticals but lowers the price target from $64 to $57.
September 13, 2024 | 7:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
JP Morgan analyst Anupam Rama maintains an Overweight rating on Apellis Pharmaceuticals but lowers the price target from $64 to $57.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100